Oral contraceptive efficacy and antibiotic interaction...

[Guest guest]

Hi,

I found this abstract relating to oral contraceptives and antibiotics

in the June 2002 issue of the Journal of the American Academy of

Dermatology.

I hope this helps someone!

Matija

Oral contraceptive efficacy and antibiotic interaction: A myth

debunked

Johanna S. M. Archer, MDa [MEDLINE LOOKUP]

F. Archer, MDb [MEDLINE LOOKUP]

ton, South Carolina, and Norfolk, Virginia

The purpose of this study was to review the pharmacokinetic and

clinical literature regarding the efficacy of oral contraceptives

when used concomitantly with antibiotic therapy. Relevant literature

was identified by searching MEDLINE and EMBASE. Other sources were

located by consulting the bibliographies of the material collected

from MEDLINE and EMBASE. Pharmacokinetic evidence demonstrates that

plasma levels of oral contraceptive steroids are unchanged with the

concomitant administration of antibiotics, including ampicillin,

ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin,

roxithromycin, temafloxacin, and tetracycline. However, reduced

steroid levels have been reported in women taking rifampin with oral

contraceptives. Clinical reports of contraceptive failure with

antibiotic use are retrospective, have multiple potential biases, and

are not supported by pharmacokinetic data. Available scientific and

pharmacokinetic data do not support the hypothesis that antibiotics

(with the exception of rifampin) lower the contraceptive efficacy of

oral contraceptives. (J Am Acad Dermatol 2002;46:917-23.)

From the Department of Obstetrics and Gynecology, Medical University

of South Carolina,a and Clinical Research Center, Institute for

Reproductive Medicine, Eastern Virginia Medical School.b

Funding sources: None.

Disclosure: F. Archer, MD, has received grants for clinical

trials from Wyeth-Ayerst Laboratories, Ortho Pharmaceutical, Organon,

Inc, Lilly, Schering Plough, Berlex Laboratories, Pharmacia Corp, and

TAP; he is a consultant to Wyeth-Ayerst Laboratories, TAP, Organon,

Inc, Lilly, Pharmacia Corp, and Schering Plough; and he serves on the

speakers' bureaus of Wyeth-Ayerst Laboratories, Organon, Inc,

Pharmacia Corp, and Lilly.

Reprint requests: Johanna S. M. Archer, MD, Department of Obstetrics

and Gynecology, Medical University of South Carolina, 96

Lucas St, Suite 634, ton, SC 29425.

Copyright © 2002 by the American Academy of Dermatology Inc.

0190-9622/2002/$35.00 + 0 16/1/120448

doi:10.1067/mjd.2002.120448

[Guest guest]

Hi,

I found this abstract relating to oral contraceptives and antibiotics

in the June 2002 issue of the Journal of the American Academy of

Dermatology.

I hope this helps someone!

Matija

Oral contraceptive efficacy and antibiotic interaction: A myth

debunked

Johanna S. M. Archer, MDa [MEDLINE LOOKUP]

F. Archer, MDb [MEDLINE LOOKUP]

ton, South Carolina, and Norfolk, Virginia

The purpose of this study was to review the pharmacokinetic and

clinical literature regarding the efficacy of oral contraceptives

when used concomitantly with antibiotic therapy. Relevant literature

was identified by searching MEDLINE and EMBASE. Other sources were

located by consulting the bibliographies of the material collected

from MEDLINE and EMBASE. Pharmacokinetic evidence demonstrates that

plasma levels of oral contraceptive steroids are unchanged with the

concomitant administration of antibiotics, including ampicillin,

ciprofloxacin, clarithromycin, doxycycline, metronidazole, ofloxacin,

roxithromycin, temafloxacin, and tetracycline. However, reduced

steroid levels have been reported in women taking rifampin with oral

contraceptives. Clinical reports of contraceptive failure with

antibiotic use are retrospective, have multiple potential biases, and

are not supported by pharmacokinetic data. Available scientific and

pharmacokinetic data do not support the hypothesis that antibiotics

(with the exception of rifampin) lower the contraceptive efficacy of

oral contraceptives. (J Am Acad Dermatol 2002;46:917-23.)

From the Department of Obstetrics and Gynecology, Medical University

of South Carolina,a and Clinical Research Center, Institute for

Reproductive Medicine, Eastern Virginia Medical School.b

Funding sources: None.

Disclosure: F. Archer, MD, has received grants for clinical

trials from Wyeth-Ayerst Laboratories, Ortho Pharmaceutical, Organon,

Inc, Lilly, Schering Plough, Berlex Laboratories, Pharmacia Corp, and

TAP; he is a consultant to Wyeth-Ayerst Laboratories, TAP, Organon,

Inc, Lilly, Pharmacia Corp, and Schering Plough; and he serves on the

speakers' bureaus of Wyeth-Ayerst Laboratories, Organon, Inc,

Pharmacia Corp, and Lilly.

Reprint requests: Johanna S. M. Archer, MD, Department of Obstetrics

and Gynecology, Medical University of South Carolina, 96

Lucas St, Suite 634, ton, SC 29425.

Copyright © 2002 by the American Academy of Dermatology Inc.

0190-9622/2002/$35.00 + 0 16/1/120448

doi:10.1067/mjd.2002.120448